Diana Campelo Delgado,  —

Researchers at the Sheffield Institute for Translational Neuroscience (SITraN) have been awarded £1.2 million ($1.67 million) from Parkinson’s UK to develop new treatments that slow progression of the disease. “This new funding will greatly accelerate the project and shows our commitment to working with ground-breaking academic researchers in the UK…

Centogene has completed enrollment of 10,000 participants in its two-year global study assessing the contribution of genetic factors in the development of Parkinson’s disease. “We are pleased to have reached such a pivotal point in our Parkinson’s disease study,” Peter Bauer, MD, chief genomic officer at Centogene, said…

Abbott has launched its NeuroSphere Virtual Clinic, a U.S. Food and Drug Administration (FDA)-approved digital technology that allows remote patient-doctor communication, increasing medical care access for patients with Parkinson’s disease and other movement disorders. “NeuroSphere Virtual Clinic solves considerable issues patients with movement disorders, such as Parkinson’s disease…

Practicing golf may have more benefits than tai chi for improving mobility and balance in people with Parkinson’s disease, simply because it might be more enjoyable, a small study reports. The study “Feasibility and Tolerability Randomized Clinical Trial of Golf Versus Tai Chi for People with Moderate Parkinson’s…

A $1-million grant has made it possible for the University of Miami Miller School of Medicine to be added to the PD GENEration study, a nationwide initiative seeking to increase the availability of genetic counseling for people with Parkinson’s disease in the U.S. “We are truly grateful for the…

AbbVie has purchased an exclusive right to acquire Mitokinin, which includes its PINK1 clinical program for the potential treatment of Parkinson’s disease. Under this agreement, Mitokinin will receive an upfront payment and continue to develop its PINK1 compounds by completing an investigational new drug (IND) application and enabling…

IMAC Holdings has completed dosing the first group of participants in a Phase 1 clinical trial evaluating its investigational umbilical cord-derived mesenchymal stem cells (MSCs) as a potential treatment for bradykinesia, a common motor symptom of Parkinson’s disease. The group consists of five patients who received a…

Newronika‘s AlphaDBS, an innovative deep brain stimulation (DBS) system being evaluated in patients with Parkinson’s disease, has received CE Mark approval in Europe. The CE Mark is a seal of approval issued by the European Commission that means products have been assessed to meet pre-established safety, health,…

Biogen and Sangamo Therapeutics have begun a collaboration to develop and commercialize gene therapies for Parkinson’s and Alzheimer’s diseases, as well as an undisclosed neuromuscular disease. The five-year collaboration will join Sangamo’s science expertise and proprietary technology with Biogen’s clinical development capabilities. The goal is to submit investigational…

Cure Parkinson’s is supporting AbFero Pharmaceuticals in its work to advance SP-420, a potential disease-modifying therapy for Parkinson’s disease that clears excess iron from the brain. The grant award supports further testing of AbFero’s lead compound in Parkinson’s models with a goal of moving it into clinical trials. SP-420, a next-generation iron…